Europe — EMA
Miglustat Dipharma
GNH USA supplies Miglustat Dipharma (Miglustat), a glucosylceramide synthase inhibitor for Gaucher disease type 1 and Niemann-Pick disease type C.
Request sourcing
What is Miglustat?
Miglustat, the active ingredient in Miglustat Dipharma, is a glucosylceramide synthase inhibitor presented as a oral tablet for oral use. It treats Gaucher disease type 1 and Niemann‑Pick disease type C in patients who meet specific clinical criteria.
GNH USA supplies Miglustat Dipharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.
What is Miglustat used for?
Miglustat is used to manage lysosomal storage disorders that involve glycosphingolipid accumulation. - Gaucher disease type 1: reduces spleen and liver size, improves blood counts and bone health. - Niemann‑Pick disease type C: slows neurological decline and stabilises hepatic function. - Patients unsuitable for enzyme‑replacement therapy: provides an oral therapeutic alternative.
What are the side effects of Miglustat?
Miglustat may cause a range of adverse reactions, from mild to serious.
Common Side Effects: - Diarrhoea: frequent loose stools, often mild to moderate. - Nausea: sensation of queasiness that may affect appetite. - Weight loss: gradual reduction in body weight during therapy. - Abdominal pain: discomfort or cramping in the stomach area.
Serious or Rare Side Effects: - Pancreatitis: inflammation of the pancreas requiring immediate medical attention. - Severe allergic reaction: symptoms such as rash, swelling, or difficulty breathing. - Elevated liver enzymes: may indicate hepatic stress and need monitoring.
What precautions apply to Miglustat?
Before initiating therapy, several safety considerations should be reviewed. - Dose adjustment: modify dose in patients with renal impairment. - Monitor: perform periodic liver function tests during treatment. - Avoid: concurrent use of strong CYP3A4 inhibitors, which can raise miglustat levels. - Pregnancy: safety not established; weigh potential benefits against risks. - Store at below 25°C: keep in the original pack, protect from moisture.
What does Miglustat interact with?
Miglustat can interact with other medicines, requiring careful management.
Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase miglustat exposure and toxicity. - Other glucosylceramide synthase inhibitors: additive effects can raise risk of adverse events.
Moderate Interactions (Monitor Closely): - Antidiabetic agents: may enhance hypoglycaemia risk. - Warfarin: potential alteration of INR values. - Oral contraceptives: miglustat may reduce hormonal efficacy.
